Does the media prefer MGTX or EWTX?

In the previous week, Edgewise Therapeutics had 16 more articles in the media than MeiraGTx. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.24 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CPRX or MGTX?

In the previous week, MeiraGTx had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 2 mentions for MeiraGTx and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.00 equaled MeiraGTx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VKTX or MGTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 10 mentions for Viking Therapeutics and 2 mentions for MeiraGTx. Viking Therapeutics' average media sentiment score of 1.23 beat MeiraGTx's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or DNLI?

In the previous week, Denali Therapeutics had 9 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for MeiraGTx. Denali Therapeutics' average media sentiment score of 0.31 beat MeiraGTx's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MGTX or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for MeiraGTx. Tango Therapeutics' average media sentiment score of 0.50 beat MeiraGTx's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$13.03 -0.04 (-0.34%)

As of 01:41 PM Eastern

Compare

MGTX vs. EWTX, CPRX, VKTX, DNLI, and TNGX

Should you buy MeiraGTx stock or one of its competitors? MarketBeat compares MeiraGTx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MeiraGTx include Edgewise Therapeutics (EWTX), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and Tango Therapeutics (TNGX).

How does MeiraGTx compare to Edgewise Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Edgewise Therapeutics (NASDAQ:EWTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

MeiraGTx presently has a consensus price target of $26.00, suggesting a potential upside of 99.60%. Edgewise Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 12.42%. Given MeiraGTx's higher probable upside, equities research analysts clearly believe MeiraGTx is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Edgewise Therapeutics had 16 more articles in the media than MeiraGTx. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.24 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

MeiraGTx has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.82	-$114.20M	-$1.48	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

MeiraGTx beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, suggesting a potential upside of 1.62%. MeiraGTx has a consensus price target of $26.00, suggesting a potential upside of 99.60%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, MeiraGTx had 1 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 2 mentions for MeiraGTx and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 0.00 equaled MeiraGTx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to MeiraGTx's net margin of -151.12%. Catalyst Pharmaceuticals' return on equity of 35.76% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
MeiraGTx	-151.12%	N/A	-54.96%

Catalyst Pharmaceuticals has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
MeiraGTx	$81.39M	14.82	-$114.20M	-$1.48	N/A

Summary

Catalyst Pharmaceuticals beats MeiraGTx on 10 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Viking Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

In the previous week, Viking Therapeutics had 8 more articles in the media than MeiraGTx. MarketBeat recorded 10 mentions for Viking Therapeutics and 2 mentions for MeiraGTx. Viking Therapeutics' average media sentiment score of 1.23 beat MeiraGTx's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics presently has a consensus price target of $97.88, indicating a potential upside of 186.49%. MeiraGTx has a consensus price target of $26.00, indicating a potential upside of 99.60%. Given Viking Therapeutics' higher probable upside, research analysts plainly believe Viking Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

MeiraGTx has higher revenue and earnings than Viking Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
MeiraGTx	$81.39M	14.82	-$114.20M	-$1.48	N/A

Viking Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
MeiraGTx	-151.12%	N/A	-54.96%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

MeiraGTx beats Viking Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Denali Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

MeiraGTx has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

MeiraGTx presently has a consensus target price of $26.00, suggesting a potential upside of 99.60%. Denali Therapeutics has a consensus target price of $35.92, suggesting a potential upside of 45.26%. Given MeiraGTx's higher possible upside, research analysts clearly believe MeiraGTx is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Denali Therapeutics had 9 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Denali Therapeutics and 2 mentions for MeiraGTx. Denali Therapeutics' average media sentiment score of 0.31 beat MeiraGTx's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has higher earnings, but lower revenue than Denali Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.82	-$114.20M	-$1.48	N/A
Denali Therapeutics	$330.53M	11.87	-$512.54M	-$2.84	N/A

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Denali Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Denali Therapeutics	N/A	-55.27%	-44.24%

Summary

Denali Therapeutics beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to Tango Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

MeiraGTx has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

MeiraGTx presently has a consensus target price of $26.00, indicating a potential upside of 99.60%. Tango Therapeutics has a consensus target price of $42.15, indicating a potential upside of 55.89%. Given MeiraGTx's higher probable upside, research analysts plainly believe MeiraGTx is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tango Therapeutics has lower revenue, but higher earnings than MeiraGTx. Tango Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.82	-$114.20M	-$1.48	N/A
Tango Therapeutics	$62.38M	62.70	-$101.59M	-$0.83	N/A

Tango Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Tango Therapeutics	N/A	-41.54%	-33.44%

In the previous week, Tango Therapeutics had 2 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Tango Therapeutics and 2 mentions for MeiraGTx. Tango Therapeutics' average media sentiment score of 0.50 beat MeiraGTx's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tango Therapeutics beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.21B	$3.72B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-8.81	9.08	269.97	24.82
Price / Sales	14.82	1,268.38	650.66	108.09
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	-186.09	17.65	11.26	6.44
Net Income	-$114.20M	-$13.25M	$3.45B	$347.27M
7 Day Performance	9.65%	5.33%	3.62%	2.55%
1 Month Performance	-2.72%	-1.83%	-0.56%	-1.02%
1 Year Performance	65.30%	61.05%	77.38%	23.33%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	3.172 of 5 stars	$13.03 -0.3%	$26.00 +99.6%	+65.9%	$1.21B	$81.39M	N/A	300	Upcoming Earnings Gap Up
EWTX Edgewise Therapeutics	2.1209 of 5 stars	$39.91 -4.1%	$48.75 +22.2%	+243.2%	$4.30B	N/A	N/A	60	News Coverage Earnings Report Analyst Revision
CPRX Catalyst Pharmaceuticals	3.0723 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80
VKTX Viking Therapeutics	3.5549 of 5 stars	$33.03 -5.3%	$97.00 +193.7%	-9.6%	$3.85B	N/A	N/A	20	Positive News
DNLI Denali Therapeutics	2.7369 of 5 stars	$23.54 -0.1%	$35.17 +49.4%	+77.9%	$3.74B	$330.53M	N/A	430	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. EWTX, CPRX, VKTX, DNLI, and TNGX

How does MeiraGTx compare to Edgewise Therapeutics?

Summary

How does MeiraGTx compare to Catalyst Pharmaceuticals?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Summary

How does MeiraGTx compare to Denali Therapeutics?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. EWTX, CPRX, VKTX, DNLI, and TNGX

How does MeiraGTx compare to Edgewise Therapeutics?

Do analysts rate MGTX or EWTX?

Does the media prefer MGTX or EWTX?

Which has more risk and volatility, MGTX or EWTX?

Is MGTX or EWTX more profitable?

Which has higher valuation and earnings, MGTX or EWTX?

Do insiders and institutionals hold more shares of MGTX or EWTX?

Summary

How does MeiraGTx compare to Catalyst Pharmaceuticals?

Do analysts recommend CPRX or MGTX?

Does the media favor CPRX or MGTX?

Do insiders & institutionals hold more shares of CPRX or MGTX?

Which has more volatility & risk, CPRX or MGTX?

Is CPRX or MGTX more profitable?

Which has better valuation and earnings, CPRX or MGTX?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Which has more risk and volatility, VKTX or MGTX?

Does the media prefer VKTX or MGTX?

Do analysts prefer VKTX or MGTX?

Which has higher valuation & earnings, VKTX or MGTX?

Is VKTX or MGTX more profitable?

Do institutionals and insiders have more ownership in VKTX or MGTX?

Summary

How does MeiraGTx compare to Denali Therapeutics?

Which has more volatility and risk, MGTX or DNLI?

Do analysts rate MGTX or DNLI?

Does the media favor MGTX or DNLI?

Which has preferable earnings and valuation, MGTX or DNLI?

Do insiders & institutionals have more ownership in MGTX or DNLI?

Is MGTX or DNLI more profitable?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Which has more risk & volatility, MGTX or TNGX?

Do analysts prefer MGTX or TNGX?

Do institutionals & insiders have more ownership in MGTX or TNGX?

Which has stronger earnings and valuation, MGTX or TNGX?

Is MGTX or TNGX more profitable?

Does the media favor MGTX or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools